CN101099799B - Medicine for treating leucoderma by melanin regeneration - Google Patents
Medicine for treating leucoderma by melanin regeneration Download PDFInfo
- Publication number
- CN101099799B CN101099799B CN2006100454781A CN200610045478A CN101099799B CN 101099799 B CN101099799 B CN 101099799B CN 2006100454781 A CN2006100454781 A CN 2006100454781A CN 200610045478 A CN200610045478 A CN 200610045478A CN 101099799 B CN101099799 B CN 101099799B
- Authority
- CN
- China
- Prior art keywords
- medicine
- weight portions
- treatment
- radix
- melanin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention is concerned with a kind of medicine for curing leucoderma with melanin regeneration. It relates to balloonflower root, ducksmeat, tribulus terrestris, red sage root, angelica, chuanxiong rhizome, psoralea fruit, astragalus root in proportion. It takes effect quickly, just for 1 to 4 days, and it has short period of treatment, only for 1 to 2 times, and it has high cwith 84.2 percent of whole curative ratio and it is difficult to recurrence. It can reduce the blood viscosity and flowing property, improve microcirculation, enhance content of ceruloplasmin, reduce humoral immunity and enhance cellular immune function to promote melanin regeneration of skin. It has unconspicuous side reaction and effective safety for clinic application with low cost. It is easy for preparation to lighten economy burden of sick.
Description
Technical field
The present invention relates to the leukodermic medicine of a kind of treatment, specifically a kind of is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Background technology
Vitiligo is claimed again to lose disease in vain, is limitation white patch to occur with skin, and expanding gradually then is the dermatosis of main clinical manifestation.The sickness rate of vitiligo in natural crowd is about 0.15%～2%, also has report to be about 1～2% abroad; Primary disease can be with area, ethnic group, the colour of skin and is different.Along with the acceleration of process of industrialization, environmental pollution is serious day by day, and multiple factor such as iatrogenic, drug-induced disease surge all impels leukodermic sickness rate to increase year by year.The dark more people's sickness rate of general colour is high more.Though leucoderma disease is superficial, corroding the skin and the soul of patient health, badly damaged people's appearance, the spirit of dampening the people influences its orthobiosis, marriage, work and social activity, is one of worldwide difficult treatment.
Though domestic also have some to treat leukodermic Chinese patent medicine, take effect slow, the course of treatment is long, cure rate is low, curative effect is undesirable, production cost is high, patient economy burden is heavy.See that from domestic and international clinical treatment situation therapy for vitiligo still is in the stage that produce effects is slow, the course of treatment is long, cure rate is low.
Summary of the invention
Technical problem to be solved by this invention is a kind of have lung qi dispersing circulation of qi promoting, promoting blood circulation to remove obstruction in the collateral to be provided, microcirculation improvement, adjusting humoral immunity of organism and cellular immunization, the leukodermic medicine of treatment of recovery melanin regeneration function.
Solution of the present invention is based on motherland's traditional medicine to pathogenetic understanding of vitiligo and Therapeutic Principle, in conjunction with present-day medical knowledge, starts with from lung and meridians; Leukodermic etiology and pathogenesis has been carried out the analysis and the research of system; It is brand-new theoretical creatively to have proposed " black and white is ruled together with sick, black and white ", on this basis, nurses one's health the scheme that combines with topical therapeutic according to integral body; Achieve with reference to modern pharmacological research; From motherland's medical treasure-house, filter out the natural edible-plant medicine of lung qi dispersing gas, the meridian dredging, lively atmosphere blood, the body resistance strengthening and constitution consolidating, according to the theory of Chinese medical science prescription; Skim the cream off milk; Make its performance microcirculation improvement, regulate humoral immunity of organism and effects such as cellular immunization, recovery melanin regeneration function, adopt medicines such as Radix Platycodonis, Herba Spirodelae, Fructus Tribuli, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Fructus Psoraleae, the Radix Astragali to form basic prescription, developed a kind of medicine of treating leucoderma by melanin regeneration.
The present invention is achieved in that a kind of medicine of treating leucoderma by melanin regeneration, and the medicine material of processing effective ingredient consists of,
Radix Platycodonis 6～18 weight portions
Herba Spirodelae 5～15 weight portions
Fructus Tribuli 9～20 weight portions
Radix Salviae Miltiorrhizae 6～18 weight portions
Radix Angelicae Sinensis 6～15 weight portions
Rhizoma Chuanxiong 6～15 weight portions
Fructus Psoraleae 10～18 weight portions
The Radix Astragali 6～15 weight portions.
The clinical use result of the present invention's medicine shows that advantage is arranged:
1) instant effect, 1-4 days take effect; Short treating period, cure general 1-2 the course of treatment; Cure rate is high, total cure rate 84.2%; Be difficult for recurrence.
2) have blood viscosity lowering, increase blood fluidity, microcirculation improvement, raising Ceruloplasmin content, reduce humoral immunization and strengthen the effect of cellular immune function, promote the skin melanin regeneration.
3) do not see that tangible toxicity is arranged, clinical practice is safe and effective.
4) expense is low.Compare with the leukodermic medicine of similar treatment, have cost low, be easy to advantages such as preparation, can alleviate patient's financial burden.
The specific embodiment
Further specify the present invention below.
The optimum weight proportioning of processing the medicine material of effective ingredient does
Radix Platycodonis 9～15 weight portions
Herba Spirodelae 8～12 weight portions
Fructus Tribuli 10～15 weight portions
Radix Salviae Miltiorrhizae 9～16 weight portions
Radix Angelicae Sinensis 9～12 weight portions
Rhizoma Chuanxiong 9～12 weight portions
Fructus Psoraleae 12～16 weight portions
The Radix Astragali 9～12 weight portions.
A kind of method for preparing of the present invention's medicine is:
1), above-mentioned raw materials is cleaned, dried and cuts or smash to pieces;
2), with Rhizoma Chuanxiong, the Radix Astragali, Radix Angelicae Sinensis, Radix Platycodonis with cold water soak 15～25 minutes, decoct and extracted 30～40 minutes, filter, take out filtrating, and then add water, decocted 30～40 minutes, filtration merges filtrating twice.Filtrating after merging is concentrated with the cryogenic vacuum method, to the thick paste shape, dry, be ground into fine powder, cross 80～100 mesh sieves, for use;
3), the other medicines raw material was ground into the fine powder of 50～150 mesh sieves, again with above-mentioned extractum mix homogeneously, granulated then, drying, processed the granule of the present invention's medicine.
Certainly, the present invention's medicine also can be processed dosage forms such as being fit to oral powder, capsule.
For showing medicine of the present invention to leukodermic therapeutic effect, we have carried out clinical treatment research to 413 routine patients with vitiligo.In the research, the leukodermic Clinical typing and the diagnostic criteria diagnoses and treatment of formulating according to Chinese combination of Chinese and Western medicine Society of Dermatology and Venereology.
413 routine clinical symptoms typical cases.Get rid of that the depigmentation left over after some deflorescence, nevus anemicus, albinism, senile white macula, sight are bathed the property white macula, are associated with serious primary disease such as blood vessel, kidney and hemopoietic system, the psychotic, not do not judge case such as curative effect person by regulation medication, data completely without method.
262 routine patients with vitiligo are seminar, and the clinical symptoms typical case is according to the theory of Chinese medical science differentiation of symptoms and signs for classification of syndrome.Therapeutic Method is the granule of the present invention's for oral administration medicine, and 2 times on the one, each 5g respectively obeys 1 time sooner or later.
Select that medical history, the state of an illness, age are suitable with seminar, 151 routine patients with vitiligo of comparability are arranged is matched group.The treatment of control group method is BAILING PIAN for oral administration (produce in Guangdong, and lot number is 961106), one time 4,3 times on the one.
Two groups are three months a course of treatment, but continuous use 2-4 course of treatment.
1) histopathological examination method
To draw materials with the marginal portion in the white macula, with Fang Tena (Fontana) and DOPA (Dopa) staining, light microscopic the spy dye, and observes treatment front and back melanocyte and melanin granule.
Before the treatment, early stage skin lesion stratum basale melanocyte reduces, and late period, skin lesion district melanocyte lacked fully, and DOPA dyeing or silver dyeing do not show melanocyte, the visible big and melanocyte of distortion in edge, and branch is prominent long and be full of melanin granule.After the healing, visible white macula district and edge melanocyte form are normal.
2) statistical method
Collect all clinical datas of each patient, use t check and X
2Check is carried out statistical procedures to data.
3) criterion of curative effect: with reference to Ministry of Health of the People's Republic of China " new Chinese medicine clinical research guideline ", recovery from illness: the white macula complete obiteration, recover the normal colour of skin, histopathological examination is normal.Produce effects: white macula disappears more than 50%, white macula disappearance part, and histopathological examination is normal.Effectively: white macula disappears and accounts for 20%～50% of original area, or more pigment island is arranged in white macula, and there have pigment demutation place to do histopathological examination to be normal.Invalid: no change or white macula enlarge before and after the treatment.
The clinical treatment result finds that 243 examples that 262 routine patients took effect in the seminar account for 92.7% in 1-4 days; 8 examples that took effect in 5-10 days account for 3.1%; 7 examples that took effect in 11-30 days account for 2.7%, and total effective rate is 98.5%.
And in the matched group 151 routine patients 10 days with interior 0 example that takes effect, 6 examples of imitating in 11-30 days account for 3.97%; 17 examples of imitating in 31-90 days account for 11.2%; 52 examples that took effect in 91-180 days account for 34.4%, total effective rate 49.7%.
The total effects contrast situation of seminar and matched group is seen table 1.
Table 1 seminar and matched group total effects are relatively
X
2＝245.04 P<0.001
Seminar's cure rate 69.8%, matched group cure rate 3.9%, seminar is 17.9 times of matched group.Seminar's total effective rate 98.5%, matched group total effective rate 49.7%, seminar is 1.98 times of matched group.Seminar obviously is superior to matched group.The contrast of two groups cure rate, total effective rate through statistical procedures, has utmost point significant difference (P < 0.001).
The leukodermic efficacy result that seminar is five types is seen table 2
Five types of vitiligo efficacy results of table 2 seminar
Five types of leukodermic cure rates: it is 86.4% that spleen accumulates damp-heat type, and caused by hepatic stagnation qi stagnation is 80.9%, and the asthenia of qi and blood pattern of fever is 68.5%, and the deficiency of the liver and kindey type is 57.1%, and the meridians stasis type is 36.1%.Accumulate damp-heat type it is thus clear that curative effect is followed successively by spleen in proper order>caused by hepatic stagnation qi stagnation>weak type of qi and blood>the deficiency of the liver and kindey type>the meridians stasis type.
Seminar and matched group skin lesion (white macula) the time situation of therapeutic effect occurs and see table 3.
The time ratio that effect appears in table 3 seminar and matched group
Seminar takes effect in most of 1-4 days, and average responding time is 3.1 days; Matched group took effect in most 91-180 days, and average responding time is 109.3 days.
In one course of treatment (90 days), two groups of responding times are through statistical procedures (four form Precision Test methods), and utmost point significant difference (P < 0.005) is arranged.
In two courses of treatment (180 days), two groups of responding times are through statistical procedures, and utmost point significant difference (P < 0.001) is arranged.
Relatively see table 4 course of treatment that skin lesion recovers the normal colour of skin.
Table 4 seminar and matched group recover the course of treatment of the normal colour of skin and compare
Annotate: " 1 " of going up in the table was represented within 1 month." 2 " expression " 1 month and more than, but less than 2 months ", the rest may be inferred by analogy.
Seminar's white macula recovered normal colour of skin majority at 3-5 month, and average course of treatment is 3.72 months.The matched group majority was at 11-12 month, and average course of treatment is 11.5 months.Seminar shortens 7.78 months than matched group the course of treatment.
Two groups through statistical procedures (four form Precision Test methods), and utmost point significant difference (P < 0.005) is arranged.
Allergy and untoward reaction situation relatively see table 5.
Table 5 allergy and untoward reaction are relatively
Medicine for external use has 0.76% patient pruritus to occur slightly burning in the seminar, the red pimple of the appearance that has, and symptom is died away after the drug withdrawal.Matched group has 5.30% patient allergy and untoward reaction to occur, and two groups have significant difference through statistical procedures.
The recovery from illness patient follows up a case by regular visits to and relatively sees table 6.
Table 6 recovery from illness patient follows up a case by regular visits to comparison (%)
Two groups of part cured persons carry out the follow-up investigation of half a year to three year. and seminar's relapse rate 3.8%, matched group are 83.3%.Follow up a case by regular visits to the patient to two groups and carry out statistical procedures (four form Precision Test methods), utmost point significant difference (p < 0.005) is arranged.
Can find out through above comparison, the present invention's medicine have instant effect, short treating period, cure rate high, have no adverse reaction, be difficult for characteristics such as recurrence, therapeutic effect is superior to matched group greatly.
Be the experimentation data below.
42 routine patients with in the above-mentioned seminar are observation group, are matched group with 40 routine healthy persons, the detection of the hemorheology before and after treating respectively, immunology, ceruloplasmin.
1) hemorheology detects
Reference value: the WBV height is cut (200/s) 5.67 scholar 0.54mpa.s, low (3/s) the 7.90 scholar 1.22mPa.s that cut; Whole blood reduced viscosity: 6.06--0.32mPa.s, plasma viscosity 1.3-1.6mpa.s, ESR equation K value: 53 scholars 40, erythrocyte sedimentation rate (ESR): 0-20 (mm/h), packed cell volume: 37-47 (1/1), the result sees table 7.
Hemorheology changes (x before and after the treatment of table 7 observation group
-Scholar s, n=42)
There were significant differences before and after the ESR treatment, and P < 0.05; The WBV height is cut, WBV low is cut, whole blood reduced viscosity height is cut, the whole blood reduced viscosity low cut and the packed cell volume treatment before and after highly significant difference is all arranged, P < 0.01.
2) ceruloplasmin detects (turbidimetry)
Reference value: 0.15-0.6mg/ml, the result sees table 8
The comparison of ceruloplasmin variation and matched group before and after the treatment of table 8 observation group (x scholar s, mg/l)
Significantly be lower than matched group (P < 0.05) before the treatment of observation group Ceruloplasmin, treatment back and matched group difference do not have significance (P>0.05).Difference highly significant before and after observation group's treatment (P 0.01).
3) immunology detection
1. humoral immunization is measured
Adopt the ARRAY360 automatization special proteins analyzer of U.S. Beckman department production to measure (result sees table 9,10), reference value, 6-60 year, IgG:6.5-16.0,1gA:0.35-3.5, IgM:0.5-3.0.
Comparison (the x of immunoglobulin variation and matched group before and after the treatment of table 9 observation group
-Scholar s, g/l)
Immunoglobulin changes relatively (x before and after the treatment of table 10 observation group
-Scholar s, g/l)
< 0.01, treatment back and matched group difference do not have significance (P>0.05), have no significant change before the IsM treatment with after the treatment to be significantly higher than matched group P before the IgT gA of observation group, the IgG treatment.Have before the treatment highly significant to improve (P < 0.01) from the treatment back IgA of the visible observation group of table 10, IgG, IgM changes no significance.
2. cellular immune function assay
The detection of a.T TLC
E garland experiment (ERPT): adopt the glutaraldehyde cross-linking technology that McAb (monoclonal antibody) is combined with Shan Hong cell (SRBC), process the SRBC of sensitization.Operation in accordance with the law is with May-Gruenwalcl and the dyeing of Clemsa dye liquor, high power lens inspection; Be stained with 3 above SRBC persons around the lymphocyte; Be the garland positive cell. amount to several 200 lymphocytes, calculate rosette formation cell percentage ratio, the result sees table 11 (reference value 60%-80%).
B. lymphocyte transformation experiment (LTT):
The morphology counting method: taking heparin anticoagulant fresh blood BIAO and BEN adds mitogen phytohaemagglutinin (PHA), in accordance with the law operation.On the blood sheet, drip the dyed blended liquid of Cleffisa-Wrlght, add the Pn6.9 phosphate buffer, dry back is with 200 lymphocytes of oily sem observation, and the result sees table 11 (about reference value 70%).
The detection of table 11 T TLC and lymphocyte transformation experiment
The detection of T TLC and lymphocyte transformation result of experiment, before the treatment, observation group is starkly lower than matched group P < 0.01, after the treatment, two of observation groups measure the result and raise, two groups of no significant differences (P>0.05).
4) microcirculation detects
(reference value: pipe loop bar is counted 8-15 bar/mm to measure nail fold microcirculation pipe loop situation with eyepiece micrometer.Pipe loop length is 100-400um).The result sees table 12.
The comparison (x scholar s) of microcirculation change and matched group before and after the treatment of table 12 observation group
Pipe is mixed bar digital display work and is lower than matched group (P < 0.05) before the observation group treatment, and an input diameter, an output diameter, loop top diameter, pipe loop length all highly significant are lower than matched group (P < 0.01).After the treatment, pipe loop bar number not only recovers but also significantly exceeds matched group (P < 0.01).Inlet branch directly recovers normally, with matched group indifference (P>0.05).Apparent in view improvement before output caliber and the treatment, but with matched group more variant than still (P < 0.05).Loop top diameter treatment back has clear improvement before the treatment, but still has notable difference (P < 0.01) with the matched group ratio.Pipe loop length treatment back recovers normal, and highly significant ground has surpassed matched group (P < 0.01).
Find through above experimental result; Most indexs such as hemorheology of finding the patient before the treatment show all obviously that unusually present a kind of tangible high blood viscosity and microcirculation disturbance, Ceruloplasmin is also obviously low than the normal person; Immunoglobulin IgA, IgG are apparently higher than the normal person; Humoral immune function strengthens, and T TCS, lymhocyte transformation rate reduce, and cellular immune function is low.Treatment back each item index obviously improves, and shows that the granule of the present invention's medicine has the effect of blood viscosity lowering, increase blood fluidity, microcirculation improvement, raising Ceruloplasmin content, reduction humoral immunization and enhancing cellular immune function.
We think thus, and the lung qi of human body is impaired, and the lung meridian QI-blood circulation is not smooth, and skin must not nourish, and causes depigmentation.The present invention's medicine through the QI invigorating lung qi dispersing increasing immunologic function, through promoting blood circulation to remove obstruction in the collateral improving hemorheology and microcirculation, thereby reach the function of recovering melanin regeneration.
The traditional Chinese medical science thinks that vitiligo and ailment said due to cold or exposure are attacked table, Lung Qi obstraction, and stagnation of QI and blood, deficiency of vital QI is relevant, so form basic prescription with medicines such as Radix Platycodonis, Herba Spirodelae, Fructus Tribuli, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, the Radix Astragali, Fructus Psoraleaes.Radix Platycodonis toil in the side and putting down, hardship are let out and are hotly loose the dispersing and elevation lung qi; Herba Spirodelae is hot cold, the light weight come-up, the function lung qi dispersing is delivered, " surgery great achievement " once with prescription, Herba Spirodelae ball by name, the kind white macula of controlling; Hot the loosing of Fructus Tribuli dispeled the wind.Single the grinding into powder with these article of " prescriptions worth thousand gold " record taken after mixing it with water, specially curing vitiligo.Common a surname of medicine-feeding sends out a lung qi, delivers and dispels the wind, and delivers to help lung qi dispersing, lung qi dispersing to be beneficial to deliver, be aided with mutually and coordinate.Lung governing skin and hair, transporation of body fluid.Lung qi a surname sends out normal, and body fluid must be failed, and spreading is in fur, the fur autotrophy.The mensuration that we combine hemorheology to learn, patients with vitiligo hemorheology cement degree increases, and is unfavorable for flowing of blood, so we have selected the hot temperature of Rhizoma Chuanxiong again for use, the Radix Salviae Miltiorrhizae bitter cold, Radix Angelicae Sinensis Gan Xinwen, the most acrid in the mouth benefaction of three medicines all can blood circulation promoting and blood stasis dispelling.Rhizoma Chuanxiong again can circulation of qi promoting, and the capable then blood of gas is capable, share and brings out the best in each other.Blood stasis does not go, and fresh blood is not given birth to, failure of skin and muscle to be nourished.Medicine bleeding from anus ventilation row, fresh blood is prone to give birth to, and skin is from profit.Both lung qi dispersing dispeled the wind, and blood-activating and qi-promoting helps the recovery of local patholoic change again.Radix Angelicae Sinensis is gentle still can enrich blood, Radix Astragali benefiting QI for strengthening the superficies, Fructus Psoraleae reinforcing the kidney and supporting YANG.The compatibility negative and positive of qi and blood is all mended each other, takes into account healthy energy to improve patient's body constitution, builds up resistance.All medicines share the merit of playing lung qi dispersing gas, dispelling wind evil, qi and blood circulation promotion altogether, setting upright gas.In addition, find that through experimentation patients with vitiligo exists some immunologic function disorders, it is hyperfunction lowly to reach humoral immunization like some cellular immunization.After treatment, improvement is in various degree arranged.So we have selected the medicine of regulating immunologic function again emphatically for use.Like the Radix Astragali, Rhizoma Chuanxiong etc. immune system all had certain dual regulation.Fructus Psoraleae then causes photosensitization, takes orally or is coated with outward, through daylight or ultraviolet radiation, can make local pigmentation.
Be the animal experiment data below.
1) experiment material
The granule of the present invention's medicine with its grinding, is configured to suspension with distilled water; 2g/ml; Be divided into high, medium and low three dose groups, irritate clothes suspension 20g/kg, 10g/kg, 5g/kg respectively, be equivalent to 21.51 times, 10.75 times, 5.38 times of clinical human dosage respectively to animal.
BAILING PIAN, Foshan pharmacy one factory, lot number is 9805003-059, with its grinding, is configured to suspension with distilled water, 4 ℃ store for future use.Animal consumption 1.5g/kg is equivalent to 12.5 times of clinical human dosage.
Levodopa (L-DA), Mushroom Tyrosinase, phytohemagglutinin (PHA), Sigma Company products.
Posterior pituitary injection, Tian Feng pharmaceutical factory, Shanghai, lot number is 9801002.
1, the 4-hydroquinone, chemical reagent factory in Beijing produces, lot number 980806.
721 spectrophotometers, Shanghai analytical tool factory.
LDF-2 type microcirculation blood flow analyzer, Tianjin Electronic Instruments Plant of Nankai.
Experiment is with Kunming white mouse, black flower Cavia porcellus, and laboratory animal room of Shandong Prov. Sanitation and Antiepidemic Station provides, Shandong kinoplaszm word 980103.Laboratory animal is irritated gastric capacity: white mice 20ml/kg, black flower Cavia porcellus 10ml/kg.
Experimental data adopts statistics " t " method of inspection to organize a significant difference relatively.
2) the anti-hydroquinone of the granule of the present invention's medicine causes dermal melanin minimizing experiment
60 of healthy black flower Cavia porcelluss, body weight 260-280 gram, male female having concurrently is divided into six groups at random, with depilatory the back part of animal black wool sloughed (5 * 5cm).Wherein one group is the normal control group, does not add processing; Other five groups of modeling animals are coated with twice of 5% hydroquinone 0.5ml (morning 8:00 and afternoon 15:00), 20d continuously every day outside part, back depilation district.This five treated animal gives the granule and the BAILING PIAN filling stomach of ordinary water, the present invention's medicine every day respectively simultaneously.Test 21d, with Animal Anesthesia, at its back depilation district center bark fetching skin 1 * 1cm, conventional fixedly embedded section carries out melanin dyeing with ferrous sulfate Littie method, and light microscopic is observed 80 hair follicles down, calculates wherein melanin hair follicle number, and the result sees table 13.
The anti-hydroquinone of the granule of table 13 the present invention's medicine causes dermal melanin and reduces experimental result
Annotate: each treated animal * group is 8, and all the other groups are 9.
Each group is carried out significant difference relatively with model control group.
3) granule of the present invention's medicine generates the influence of melanocyte amount to the dopachrome oxidation
Also improve with reference to methods such as Matsuda.At first with the granule of the present invention's medicine with phosphate buffer be diluted to height (100mg/ml), in the subsequent use herb liquid of (50mg/ml), low (10mg/ml) three variable concentrations.The BAILING PIAN that grinds after filtering is diluted to subsequent use medicinal liquid (50mg/ml) with phosphate buffer.With Mushroom Tyrosinase 1ml (100u) and levodopa liquid 1ml (1.5mg) mixing, 25 ℃ of incubation 5m. add the herb liquid 1ml of variable concentrations more respectively, put 25 ℃ and continue incubation 60m. with 1mol/L HCL0.2ml cessation reaction.Reactant mixture is centrifugal, 3000r/min, 15m abandons supernatant, and precipitate is washed 1 time with 60mol/L HCl, and distilled water is washed 2 times, and is centrifugal, and precipitate fully dissolves with 1mol/L NaOH3ml, and is centrifugal, and supernatant is put spectrophotometer 400nm and is disposed the O.D value.The O.D value of melanocyte growing amount medicament group is represented divided by the percentage rate of the 0.D value of blank group.The result sees table 14.
The granule of table 14 the present invention's medicine generates the melanocyte amount to the dopachrome oxidation influences experimental result
n＝9
4) the anti-pituitrin of the granule of the present invention's medicine causes the microcirculation disturbance experiment
50 of healthy mices, body weight 14-16 gram, male female dual-purpose is divided into five groups at random; Irritate the granule and the BAILING PIAN of clothes ordinary water, the present invention's medicine respectively, once a day, continuous 7d.During experiment animal is placed in the holder, expose its afterbody.Regulate laser micro circulation blood flowmeter, frequency response 12K hertz, time constant 0.22s, gain 10.Laser probe is placed animal tail China and foreign countries 1/3 intersection, and measuring this position blood flow is normal value.Animal tail vein injection pituitrin injection 0.2ml/ only repeats above mensuration behind the 2min, the result sees table 15.
The anti-microcirculation disturbance experimental result of the granule of table 15 the present invention's medicine
N=10 and matched group be * P < 0.01 relatively.
5) serum hemolysin level determination
50 of healthy mices, body weight 18-21 gram is divided into 5 groups at random, and male female half and half; Animals administer is all with experiment 2,3, once a day, and continuous 7d.Test the equal lumbar injection 5%CRBC0 of 1d animal.2ml/ only stimulates animal immune.Test 8d, win animal eyeball and get blood, centrifugal 3000 commentaries on classics/m, 10m, institute's serum of getting dilutes 100 times with NS: get dilute serum 1ml, add 5%CRBC0.5ml, 10% complement 0.5ml, mixing, 370 ℃ of water-bath incubation 30m, 0 ℃ of cessation reaction.Aforesaid liquid is centrifugal, 3000 commentaries on classics/m, 10m, supernatant is colorimetric in spectrophotometer 540nm place, surveys the 0.D value, reacts the height of serum hemolysin level with the size of 0.D value.The result sees table 16.
Table 16 serum hemolysin level determination result
6) phytohemagglutinin (PHA) stimulates lymphocyte transformation experiment (body internal stimulus revulsion)
50 of healthy male white mice, body weight 18-20 gram is divided into 5 groups at random; Animals administer is with experiment 4), once a day, continuous 7d.Test 1d and give the equal intramuscular injection PHA10ml/kg of animal, inject 3d continuously.When testing 8d, win animal eyeball, conventional smear, Switzerland's dyeing, oily mirror is 100 lymphocytes of counting down, and calculate the shared percentage rate of lymphoblast, and with reflection lymphocyte transformation situation, the result sees table 18.
Table 18 lymphocyte transformation experimental result
Show that through above pharmacodynamic study the hydroquinone of doses can make zoodermic melanin content reduce; (10g 20g/kg) can obviously resist the effect of hydroquinone, and dermal melanin content is increased and use the granule of the present invention's medicine simultaneously.Dopa oxidase is the important step of melanocyte synthesis of melanin.Experiment in vitro confirms, the granule of the present invention's of doses medicine (50mg/ml) can significantly promote dopa oxidase to generate melanin (P < 0.01).Prove absolutely; The granule of the present invention's medicine can resist the damaging action of some chemical substance to melanocyte; And can promote melanic chemosynthesis; This is that the granule of the present invention's medicine is treated one of leukodermic basic drug action, but its basic link that plays a role and mechanism wait further research and illustrates.
The experiment of anti-microcirculation disturbance shows, the granule of the present invention's medicine (5,10, but the 20g/kg) microcirculation disturbance due to the antagonism pituitrin significantly increases microcirculatory blood flow, presents the effect (P < 0.01) of microcirculation improvement.Give in the animal continuous application, the granule of heavy dose of the present invention's medicine can make the serum hemolysin level obviously raise, but show its enhancing body humoral immunity level; Its pair cell Immune Effects, only the granule of the present invention's of visible median dose medicine has potentiation, can promote lymphocyte transformation, surplus unknown significance influence.The granule of the present invention's medicine helps therapy for vitiligo undoubtedly to the effect of microcirculation and immunologic function, is one of important drug action reason of its treatment vitiligo.
In sum, the granule of the present invention's medicine can resist hydroquinone and cause dermal melanin minimizing effect, and the external melanin that promotes generates, and has microcirculation improvement and regulate humoral immunity of organism and cellular immune function.
Embodiment 1, take by weighing Radix Platycodonis 900g, Herba Spirodelae 500g, Fructus Tribuli 750g, Radix Salviae Miltiorrhizae 600g, Radix Angelicae Sinensis 750g, Rhizoma Chuanxiong 650g, Fructus Psoraleae 900g, Radix Astragali 750g cleans, dries and cuts or smash to pieces; Rhizoma Chuanxiong, the Radix Astragali, Radix Angelicae Sinensis, Radix Platycodonis with cold water soak 20 minutes, are decocted and extracted 35 minutes, filter, take out filtrating, and then add water, decocted 35 minutes, filtration merges filtrating twice.Filtrating after merging is concentrated with the cryogenic vacuum method, to the thick paste shape, dry, be ground into fine powder, cross 90 mesh sieves, for use; Other medicines were ground into 100 mesh sieve fine powders,, mixed back granulation, drying, processed the granule of the present invention's medicine again with above-mentioned extractum mix homogeneously.
Embodiment 2, take by weighing Radix Platycodonis 400g, Herba Spirodelae 600g, Fructus Tribuli 1000g, Radix Salviae Miltiorrhizae 500g, Radix Angelicae Sinensis 500g, Rhizoma Chuanxiong 650g, Fructus Psoraleae 900g, Radix Astragali 750g cleans, dries and cuts or smash to pieces; Rhizoma Chuanxiong, the Radix Astragali, Radix Angelicae Sinensis, Radix Platycodonis with cold water soak 20 minutes, are decocted and extracted 35 minutes, filter, take out filtrating, and then add water, decocted 35 minutes, filtration merges filtrating twice.Filtrating after merging is concentrated with the cryogenic vacuum method, to the thick paste shape, dry, be ground into fine powder, cross 90 mesh sieves, for use; Other medicines were ground into 100 mesh sieve fine powders,, mixed back granulation, drying, processed the granule of the present invention's medicine again with above-mentioned extractum mix homogeneously.
Embodiment 3, take by weighing Radix Platycodonis 400g, Herba Spirodelae 700g, Fructus Tribuli 500g, Radix Salviae Miltiorrhizae 750g, Radix Angelicae Sinensis 750g, Rhizoma Chuanxiong 300g, Fructus Psoraleae 600g, Radix Astragali 500g cleans, dries and cuts or smash to pieces; Rhizoma Chuanxiong, the Radix Astragali, Radix Angelicae Sinensis, Radix Platycodonis with cold water soak 20 minutes, are decocted and extracted 35 minutes, filter, take out filtrating, and then add water, decocted 35 minutes, filtration merges filtrating twice.Filtrating after merging is concentrated with the cryogenic vacuum method, to the thick paste shape, dry, be ground into fine powder, cross 90 mesh sieves, for use; Other medicines were ground into 100 mesh sieve fine powders,, mixed back granulation, drying, processed the granule of the present invention's medicine again with above-mentioned extractum mix homogeneously.
Claims (2)
1. the medicine of a treating leucoderma by melanin regeneration is characterized in that, the medicine material of processing effective ingredient consists of,
Radix Platycodonis 6～18 weight portions
Herba Spirodelae 5～15 weight portions
Fructus Tribuli 9～20 weight portions
Radix Salviae Miltiorrhizae 6～18 weight portions
Radix Angelicae Sinensis 6～15 weight portions
Rhizoma Chuanxiong 6～15 weight portions
Fructus Psoraleae 10～18 weight portions
The Radix Astragali 6～15 weight portions.
2. the medicine of a kind of treating leucoderma by melanin regeneration as claimed in claim 1 is characterized in that, wherein the weight proportion of each raw material does,
Radix Platycodonis 9～15 weight portions
Herba Spirodelae 8～12 weight portions
Fructus Tribuli 10～15 weight portions
Radix Salviae Miltiorrhizae 9～16 weight portions
Radix Angelicae Sinensis 9～12 weight portions
Rhizoma Chuanxiong 9～12 weight portions
Fructus Psoraleae 12～16 weight portions
The Radix Astragali 9～12 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100454781A CN101099799B (en) | 2006-07-08 | 2006-07-08 | Medicine for treating leucoderma by melanin regeneration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100454781A CN101099799B (en) | 2006-07-08 | 2006-07-08 | Medicine for treating leucoderma by melanin regeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101099799A CN101099799A (en) | 2008-01-09 |
| CN101099799B true CN101099799B (en) | 2012-10-31 |
Family
ID=39034351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100454781A Expired - Fee Related CN101099799B (en) | 2006-07-08 | 2006-07-08 | Medicine for treating leucoderma by melanin regeneration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101099799B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102805612A (en) * | 2012-07-17 | 2012-12-05 | 苏光森 | Gx-b advanced and new leucoderma removing rehabilitation and diagnosis system |
| CN103705605B (en) * | 2013-12-16 | 2015-07-15 | 崔夕军 | Traditional Chinese medicine for treating leucoderma |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1171962A (en) * | 1997-06-26 | 1998-02-04 | 王敬泽 | Suyuwan pill for curing leucoderma |
| CN1200293A (en) * | 1997-05-22 | 1998-12-02 | 李英志 | Bolus (or pills) for treating leukodermia |
| CN1315186A (en) * | 2000-03-30 | 2001-10-03 | 陈江辉 | Medical tea for treating leukoderma and its preparing process |
| CN1814139A (en) * | 2005-12-06 | 2006-08-09 | 师瑞乐 | Baidianling capsule |
-
2006
- 2006-07-08 CN CN2006100454781A patent/CN101099799B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1200293A (en) * | 1997-05-22 | 1998-12-02 | 李英志 | Bolus (or pills) for treating leukodermia |
| CN1171962A (en) * | 1997-06-26 | 1998-02-04 | 王敬泽 | Suyuwan pill for curing leucoderma |
| CN1315186A (en) * | 2000-03-30 | 2001-10-03 | 陈江辉 | Medical tea for treating leukoderma and its preparing process |
| CN1814139A (en) * | 2005-12-06 | 2006-08-09 | 师瑞乐 | Baidianling capsule |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101099799A (en) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101310751A (en) | Traditional Chinese medicine composition for replenishing qi and blood, preparation method and quality control method thereof | |
| CN101879291A (en) | Depression relieving and tranquilizing mixed decoction (powder) and pills | |
| CN102000164B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN101007151A (en) | Traditional Chinese medicine and its preparation for treating chronic nephritis | |
| CN102048902B (en) | Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation | |
| CN104173950B (en) | A kind of herbal composite for treating prostate cancer | |
| CN101549073B (en) | Medicament for treating idiopathic edema and preparation method thereof | |
| CN103330864A (en) | Traditional Chinese medicine composition used for treating acute nephritis and preparation method thereof | |
| CN100563630C (en) | The preparation method that is used for the treatment of the menoxenia Chinese medicine preparation | |
| CN101095900B (en) | Sichuan chrysanthemum pain-relieving capsule and method for preparing the same | |
| CN101099799B (en) | Medicine for treating leucoderma by melanin regeneration | |
| CN101804126A (en) | Application of traditional Chinese medicine composition in treating qi-blood deficiency and spleen-kidney deficiency and preparation method thereof | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN101224241B (en) | Melanin regeneration pill | |
| CN102048913B (en) | Traditional Chinese medicine preparation for treating climacteric syndrome and preparation method thereof | |
| CN103830288B (en) | Match certain herbaceous plants with big flowers extractive of general flavone and its production and use | |
| CN103191293B (en) | Sub-health-preventive drug composition and preparation method thereof | |
| CN112043773A (en) | Intelligent system preparation for conditioning physique and preventing and treating various psoriasis and preparation method thereof | |
| CN114344388B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN104491344A (en) | Use of traditional Chinese medicine preparation in preparing medicines for treating bulging, red, swelling and pain symptoms of eyes | |
| CN108403793B (en) | Medicine for treating primary dysmenorrhea and preparation method thereof | |
| CN101584851A (en) | Pharmaceutical composition for kidney nourishing, heart calming and nerve calming | |
| CN102772547B (en) | A kind of Chinese medicine composition for the treatment of lupus erythematosus | |
| CN104127493A (en) | Traditional Chinese medicine for treating rheumatic arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121031 Termination date: 20140708 |
|
| EXPY | Termination of patent right or utility model |